Deep sncRNA-seq of the PPMI cohort to study Parkinsons disease progression

Deep sncRNA-seq of the PPMI cohort to study Parkinsons disease progression. Kern, F., Fehlmann, T., Violich, I., Alsop, E., Hutchins, E., Kahraman, M., Grammes, N. L., Guimaraes, P., Backes, C., Poston, K., Casey, B., Balling, R., Geffers, L., Krueger, R., Galasko, D., Mollenhauer, B., Meese, E., Wyss-Coray, T., Craig, D. W., Van Keuren-Jensen, K., & Keller, A. bioRxiv, Cold Spring Harbor Laboratory, 2020.

Paper doi abstract bibtex

Coding and non-coding RNAs have diagnostic and prognostic importance in Parkinsons diseases (PD). We studied circulating small non-coding RNAs (sncRNAs) in 7,003 samples from two longitudinal PD cohorts (Parkinsons Progression Marker Initiative (PPMI) and Luxembourg Parkinsons Study (NCER-PD)) and modelled their influence on the transcriptome. First, we sequenced sncRNAs in 5,450 blood samples of 1,614 individuals in PPMI. The majority of 323 billion reads (59 million reads per sample) mapped to miRNAs. Other covered RNA classes include piRNAs, rRNAs, snoRNAs, tRNAs, scaRNAs, and snRNAs. De-regulated miRNAs were associated with the disease and disease progression and occur in two distinct waves in the third and seventh decade of live. Originating mostly from a characteristic set of immune cells they resemble a systemic inflammation response and mitochondrial dysfunction, two hallmarks of PD. By profiling 1,553 samples from 1,024 individuals in the NCER-PD cohort using an independent technology, we validate relevant findings from the sequencing study. Finally, network analysis of sncRNAs and transcriptome sequencing of the original cohort identified regulatory modules emerging in progressing PD patients.Competing Interest StatementThe authors have declared no competing interest.

@article {Kern2020.06.01.127092,
	author = {Kern, Fabian and Fehlmann, Tobias and Violich, Ivo and Alsop, Eric and Hutchins, Elizabeth and Kahraman, Mustafa and Grammes, Nadja Liddy and Guimaraes, Pedro and Backes, Christina and Poston, Kathleen and Casey, Bradford and Balling, Rudi and Geffers, Lars and Krueger, Rejko and Galasko, Douglas and Mollenhauer, Brit and Meese, Eckart and Wyss-Coray, Tony and Craig, David Wesley and Van Keuren-Jensen, Kendall and Keller, Andreas},
	title = {Deep sncRNA-seq of the PPMI cohort to study Parkinsons disease progression},
	elocation-id = {2020.06.01.127092},
	year = {2020},
	doi = {10.1101/2020.06.01.127092},
	publisher = {Cold Spring Harbor Laboratory},
	abstract = {Coding and non-coding RNAs have diagnostic and prognostic importance in Parkinsons diseases (PD). We studied circulating small non-coding RNAs (sncRNAs) in 7,003 samples from two longitudinal PD cohorts (Parkinsons Progression Marker Initiative (PPMI) and Luxembourg Parkinsons Study (NCER-PD)) and modelled their influence on the transcriptome. First, we sequenced sncRNAs in 5,450 blood samples of 1,614 individuals in PPMI. The majority of 323 billion reads (59 million reads per sample) mapped to miRNAs. Other covered RNA classes include piRNAs, rRNAs, snoRNAs, tRNAs, scaRNAs, and snRNAs. De-regulated miRNAs were associated with the disease and disease progression and occur in two distinct waves in the third and seventh decade of live. Originating mostly from a characteristic set of immune cells they resemble a systemic inflammation response and mitochondrial dysfunction, two hallmarks of PD. By profiling 1,553 samples from 1,024 individuals in the NCER-PD cohort using an independent technology, we validate relevant findings from the sequencing study. Finally, network analysis of sncRNAs and transcriptome sequencing of the original cohort identified regulatory modules emerging in progressing PD patients.Competing Interest StatementThe authors have declared no competing interest.},
	URL = {https://www.biorxiv.org/content/early/2020/06/01/2020.06.01.127092},
	eprint = {https://www.biorxiv.org/content/early/2020/06/01/2020.06.01.127092.full.pdf},
	journal = {bioRxiv}
}

Downloads: 0